Hanmi CEO On Success And Failure Of License Deals
No Need To Lose Hope When Assets Return
The CEO of South Korea's Hanmi Pharm shares experiences around licensing deals and turning around returned assets, identifying "great opportunities" in the near term for the country's pharma and biotech sectors as global partners continue to hunt for novel products and technologies.
You may also be interested in...
Scrip takes a look at South Korea’s out-licensing deal trends for 2021, finding that more big transactions are likely as the year moves towards its close despite a wider global slowing in activity, helped by rising innovative R&D.
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.
Encouraging new data for Spectrum/Hanmi’s poziotinib presented at ESMO may increase the chances of approval for the pan-HER inhibitor as a possible first-line therapy for NSCLC with the HER2 exon 20 insertion mutation, although the patient population is limited.